PO No :PO3030374580-361

Name : Mr.SUBHADEEP CHAKRABORTY Client Name : TATA 1MG KOLKATA

Age/Gender : 29/Male Referred By : Dr.
Patient ID : KOL607139 Collection Date : 19/May/2025 06:07AM
Barcode ID/Order ID : D20199210 / 12893432 Report Date : 19/May/2025 02:09PM
Sample Type : Whole Blood-EDTA Report Status : Final Report

HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 14.6 g/dL 13.0-17.0 Spectrophotometry
(Cyanide-free)
RBC 4.39 10^6/cu.mm 4.5 - 5.5 Impedance
HCT 43.4 % 40 - 50 Calculated
MCV 99.0 fL 83 - 101 Calculated
MCH 33.4 pg 27 - 32 Calculated
MCHC 33.7 g/dL 31.5 - 34.5 Calculated
RDW-CV 14.9 % 11.5-14 Calculated
Total Leucocyte Count 5.60 10^3/µL 4 - 10 Impedance
Differential Leucocyte Count
Neutrophils 57.8 % 40-80 DHSS/Microscopy
Lymphocytes 30.5 % 20-40 DHSS/Microscopy
Monocytes 7.5 % 2-10 DHSS/Microscopy
Eosinophils 3.6 % 1-6 DHSS/Microscopy
Basophils 0.6 % 0-2 Impedance/Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 3.24 10^3/µL 2-7 Calculated
Absolute Lymphocyte Count 1.71 10^3/µL 1-3 Calculated
Absolute Monocyte Count 0.42 10^3/µL 0.2 - 1 Calculated
Absolute Eosinophil Count 0.2 10^3/µL 0.02 - 0.5 Calculated
Absolute Basophil Count 0.03 10^3/µL 0.02-0.1 Calculated
Platelet Count 150 10^3/µL 150 - 410 Impedance/Microscopy
MPV 13.5 fl 6.5 - 12 Derived from Impedance
PDW 34.2 fl 9-17 Derived from Impedance

Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are
additionally being reported as absolute numbers of each cell in per unit volume of blood.
DHSS : Double Hydrodynamic Sequential System Flowcytometry
Calculated parameters are either derived from Impedence measure, RBC pulse measurement, RBC/platelet histograms or
formula derived.

This test has been performed at

TATA 1MG KOLKATA
Address: Plot No. Y-17, Block - EP,
Electronic Complex, Bidhannagar, Kolkata -
700091

Page 1 of 7
 PO No :PO3030374580-361

Name : Mr.SUBHADEEP CHAKRABORTY Client Name : TATA 1MG KOLKATA

Age/Gender : 29/Male Referred By : Dr.
Patient ID : KOL607139 Collection Date : 19/May/2025 06:07AM
Barcode ID/Order ID : D20199204 / 12893432 Report Date : 19/May/2025 01:50PM
Sample Type : Fluoride Plasma F Report Status : Final Report

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

FBS (Fasting Blood Sugar)

Glucose - Fasting 87 mg/dL 70 - 99 Hexokinase

Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes

Reference : American Diabetes Association

FBG higher than PPBG may be seen in both diabetics and healthy population.Low PPBG is seen
after inadequate intake or intake of non-carbohydrate meal before test, anti-diabetic medication
and strenuous activity.Also seen with Reactive hypoglycemia & Insulin resistance.

Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
Less than 7%
HbA1c

This test has been performed at

TATA 1MG KOLKATA
Address: Plot No. Y-17, Block - EP,
Electronic Complex, Bidhannagar, Kolkata -
700091

Page 2 of 7
PO No :PO3030374580-361

Name : Mr.SUBHADEEP CHAKRABORTY Client Name : TATA 1MG KOLKATA

Age/Gender : 29/Male Referred By : Dr.
Patient ID : KOL607139 Collection Date : 19/May/2025 06:07AM
Barcode ID/Order ID : D20199208 / 12893432 Report Date : 19/May/2025 04:40PM
Sample Type : Serum Report Status : Final Report

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 224 mg/dL Low (desirable): < 200 Enzymatic (CHO-POD)
mg/dL
Moderate (borderline)
200–239 mg/dL
High: >/= 240 mg/dL
Triglycerides 464 mg/dL Normal: < 150, Enzymatic, GPO
Borderline: 150 - 199,
High:200 - 499, Very
High >=500
Cholesterol - HDL 35 mg/dL Undesirable/high risk Accelerator Selective
<40mg/dL Detergent
Desirable/low
risk>=60mg/dl
Cholesterol - LDL 125 mg/dl Desirable: <100 Direct Enzymatic (CHO-
Above desirable: 100 - POD)
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 64 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 6.3 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 3.53 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 189 mg/dL Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220
Since Triglycerides are more than 400 mg/dl, LDL-C tested by Direct LDL method.

This test has been performed at

TATA 1MG KOLKATA
Address: Plot No. Y-17, Block - EP,
Electronic Complex, Bidhannagar, Kolkata -
700091

Page 3 of 7
PO No :PO3030374580-361

Name : Mr.SUBHADEEP CHAKRABORTY Client Name : TATA 1MG KOLKATA

Age/Gender : 29/Male Referred By : Dr.
Patient ID : KOL607139 Collection Date : 19/May/2025 06:07AM
Barcode ID/Order ID : D20199208 / 12893432 Report Date : 19/May/2025 04:40PM
Sample Type : Serum Report Status : Final Report

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
Repeat Lipid Profile after 10-12 hrs fasting if clinically indicated.

Note: High triglycerides levels may be seen in obesity, physical inactivity, smoking, excess alcohol intake, high carbohydrate diet,
foods rich in saturated and trans fats, type 2 diabetes, chronic renal failure, hypothyroidism, liver disorders, certain drugs (e.g.
corticosteroids,estrogens,retinoids, beta-blockers, birth control pills, diuretics) and genetic disorders (e.g. familial
hypertriglyceridemia, familial dysbetalipoproteinemia etc.)

Lipemic Sample

Comment:
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-

Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC

New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60

This test has been performed at

TATA 1MG KOLKATA
Address: Plot No. Y-17, Block - EP,
Electronic Complex, Bidhannagar, Kolkata -
700091

Page 4 of 7
PO No :PO3030374580-361

Name : Mr.SUBHADEEP CHAKRABORTY Client Name : TATA 1MG KOLKATA

Age/Gender : 29/Male Referred By : Dr.
Patient ID : KOL607139 Collection Date : 19/May/2025 06:07AM
Barcode ID/Order ID : D20199208 / 12893432 Report Date : 19/May/2025 04:40PM
Sample Type : Serum Report Status : Final Report

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months

•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.

Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

This test has been performed at

TATA 1MG KOLKATA
Address: Plot No. Y-17, Block - EP,
Electronic Complex, Bidhannagar, Kolkata -
700091

Page 5 of 7
 PO No :PO3030374580-361

Name : Mr.SUBHADEEP CHAKRABORTY Client Name : TATA 1MG KOLKATA

Age/Gender : 29/Male Referred By : Dr.
Patient ID : KOL607139 Collection Date : 19/May/2025 06:07AM
Barcode ID/Order ID : D20199206 / 12893432 Report Date : 19/May/2025 02:09PM
Sample Type : Serum Report Status : Final Report

IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method

Thyroid profile Total

T3, Total 1.09 ng/mL 0.60-1.81 CLIA
T4, Total 8.0 µg/dl 4.5-12.6 CLIA
Thyroid Stimulating Hormone - Ultra 2.949 uIU/ml 0.55-4.78 CLIA
Sensitive

Comment:

Below mentioned are the guidelines for pregnancy related reference ranges for TSH, total T3 & Total T4.

Pregnancy
TSH (μIU/mL) (as per
American Thyroid Total T3 (ng/mL) Total T4(μg/dL)
Association )
1st trimester 0.1-2.5 0.81-1.90 7.33-14.8
2nd trimester 0.2-3.0 1.00-2.60 7.93-16.1
3rd trimester 0.3-3.0 1.00-2.60 6.95-15.7

TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
Total T3 & T4 concentrations are altered by physiological or pathological changes in thyroxine binding globulin (TBG)
capacity .
The determination of free T3 & free T4 has the advantage of being independent of changes in the concentrations and
binding properties of the binding proteins.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.
For diagnostic purposes, results should be used in conjunction with other data.

TSH T3 T4 Interpretation

This test has been performed at

TATA 1MG KOLKATA
Address: Plot No. Y-17, Block - EP,
Electronic Complex, Bidhannagar, Kolkata -
700091

Page 6 of 7
 PO No :PO3030374580-361

Name : Mr.SUBHADEEP CHAKRABORTY Client Name : TATA 1MG KOLKATA

Age/Gender : 29/Male Referred By : Dr.
Patient ID : KOL607139 Collection Date : 19/May/2025 06:07AM
Barcode ID/Order ID : D20199206 / 12893432 Report Date : 19/May/2025 02:09PM
Sample Type : Serum Report Status : Final Report

IMMUNOLOGY
Test Name Result Unit Bio. Ref. Interval Method
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low Hypothyroidism

*** End Of Report ***

Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@1mg.com

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG KOLKATA
Address: Plot No. Y-17, Block - EP,
Electronic Complex, Bidhannagar, Kolkata -
700091

Page 7 of 7
 Ensuring accuracy IN every single report
Following a 3-step review process:

Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor

Have concerns regarding the report?

Reach out to our care team at care@1mg.com
or chat with us
CONNECT NOW >

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 200+ years

Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision

Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>

Get Second Opinion Order Medicines EXPLORE NOW >

Explore Financial Need Help?

Book Lab Tests
Support & more 1800-102-1618

*Clinical & Laboratory Standards Institute T&C Apply

 Running Low on Vitamin D?
Choose clinically proven , ready-to-drink1
Vitamin D3 with 34% better absorption2

34% Better Absorption*2

Palatable Taste1

Sugar Free1

LIMITED OFFER

MAT-IN-2500204 v1.0 02/25

*With DePURA, 34% higher Vitamin D3 levels are achieved as compared to
conventional formulation.
Reference: 1. Data on File 2. Marwaha, Raman K., et al. "Efficacy of micellized
vs. fat-soluble vitamin D3 supplementation in healthy school children from
20 % OFF
ON TATA 1MG
SHOP NOW!
use code:
DEP20
Northern India."Journal of Pediatric Endocrinology and Metabolism 29.12.

Are you getting

enough OMEGA 3

^ Stark KD, et al, progress in Lipid Research 2016

* Compared with competing products
to protect your heart?
Because 80%^ of people don’t!
# Optimal requirement of Omega-3 as mentioned by National Institutes
+ Reference from NCBI published article on comparative bioavailability

Choose Tata 1mg Salmon Omega 3 of Health. Dietary Supplement Label Database. 2015.

LDL

Reduces Improves Reduces

Triglyceride Levels Good Cholesterol Inflammation

Why Choose Us?

50% Higher Absorption+
with Triglyceride form 50% Lower
Saturated Fats*
Every batch
Tested and Certified

Upto 30% off Shop Now